MOEXIPRIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Moexipril Hydrochloride patents expire, and what generic alternatives are available?
Moexipril Hydrochloride is a drug marketed by Apotex Inc, Chartwell Rx, Glenmark Generics, Teva, Glenmark Pharms, and Heritage Pharms. and is included in eight NDAs.
The generic ingredient in MOEXIPRIL HYDROCHLORIDE is hydrochlorothiazide; moexipril hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.
Summary for MOEXIPRIL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Clinical Trials: | 6 |
Patent Applications: | 1,153 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MOEXIPRIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MOEXIPRIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Nebraska | Phase 4 |
Teva Pharmaceuticals USA | Phase 1 |
Mayo Clinic | Phase 2 |
Pharmacology for MOEXIPRIL HYDROCHLORIDE
Drug Class | Angiotensin Converting Enzyme Inhibitor |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |